In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, when a causative role of the drug is implausible, suggested stepped-up ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

Compared with currently available insulin secretagogues, DPP-4 inhibitors, by enhancing biologically active (intact) GLP-1, increase insulin secretion and suppress glucagon secretion in a glucose ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

Citing follow-up data for up to 10 years, the researchers noted that out of 12,351 patients on GLP-1s, only 278 developed dementia. In contrast, 1,849 on DPP-4 inhibitors and 2,480 on sulfonylurea ...

DPP-4 inhibitor cases were generally older, more often male, and had lower rates of psychiatric disorders and obesity than GLP-1 RA cases. However, the association between DPP-4 inhibitor use and ...

analyzed Medicare data from 2017 through 2020 and compared GLP-1 users with SGLT-2 inhibitor and DPP-4 inhibitor users. Guo's group found that GLP-1 users didn't have an increased risk for ...

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...